CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN), a specialized
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin peptide
receptor systems, today announced a featured speaker presentation
and two poster presentations at the upcoming TIDES USA hybrid conference in Boston, Massachusetts on September 20-23, 2021.
"We are excited to continue our partnership with TIDES to
continue informing the peptide world about our robust pipeline of
melanocortin agonists as possible treatments for inflammatory
conditions," said Carl Spana, Ph.D.,
President and Chief Executive Officer of Palatin. "The gut,
as well as the eye, offer multiple unique opportunities for
melanocortins to promote resolution of inflammation."
Dr. Spana is a featured speaker and will discuss the Company's
broad expertise in melanocortin peptides, including its development
programs for inflammation. The poster presentations by John Dodd, Ph.D., Senior Vice President of
Preclinical Research, demonstrates the possible utility of
melanocortins in inflammation, and presents animal disease model
data specific to colon inflammation.
TIDES USA is conducting a
hybrid live and digital event with presentations across multiple
drug development functional groups from development through
commercialization for oligos, peptides, mRNA and genome editing
products.
Presentation and Poster details are:
- Featured Speaker presentation entitled "Development of
Melanocortin-based Peptide Therapeutics: Vyleesi (FDA Approved) and
Next Generation of Novel Peptides That Resolve Inflammation" will
be presented on September 21, 2021,
by Dr. Spana.
- Two poster presentations by Dr. Dodd, provide an overview of
the exciting potential utility of melanocortin agonists for the
treatment of inflammatory diseases, with the second poster
providing specific data in an inflammatory disease rat model. The
posters are titled:
-
- Probing the Role of the Melanocortin Receptor Agonists in
Experimental Immune-Mediated Diseases
- Effect of the Melanocortin Receptor Agonist PL8177 on
DSS-Induced Colitis in Rats and a Toxicologic Assessment of PL8177
in Beagle Dogs
Both poster presentations will be available on the TIDES
USA conference website for
registered attendees and will be available on Palatin's website
today at www.palatin.com.
About Melanocortins and Inflammation
The melanocortin receptor ("MCr") system has effects on food
intake, metabolism, sexual function, inflammation, and immune
system responses. There are five melanocortin receptors, MC1r
through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have significant pharmacological effects.
Many tissues and immune cells located in the eye express
melanocortin receptors, empowering our opportunity to directly
activate natural pathways to resolve disease inflammation.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin and natriuretic peptide receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.palatin.com.
Forward-looking Statements
Statements in this press release that are not historical facts,
including statements about future expectations of Palatin, such as
statements about clinical trial plans and potential results for
peptides under development to resolve inflammation and inflammatory
diseases, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Palatin intends
that such forward-looking statements be subject to the safe harbors
created thereby. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
Palatin's actual results to be materially different from its
historical results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating for events that
occur after the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-to-present-peptides-platform-at-the-tides-usa-conference-301377246.html
SOURCE Palatin Technologies, Inc.